vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and National Storage Affiliates Trust (NSA). Click either name above to swap in a different company.
National Storage Affiliates Trust is the larger business by last-quarter revenue ($187.0M vs $183.1M, roughly 1.0× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 12.2%, a 1.1% gap on every dollar of revenue. On growth, National Storage Affiliates Trust posted the faster year-over-year revenue change (-1.6% vs -1.8%). National Storage Affiliates Trust produced more free cash flow last quarter ($299.8M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -2.4%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
National Storage Affiliates Trust is a U.S.-headquartered real estate investment trust focused on self-storage assets. It owns, operates and acquires self-storage facilities across dozens of U.S. states, offering secure storage solutions for residential and commercial customers.
AMPH vs NSA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $187.0M |
| Net Profit | $24.4M | $22.9M |
| Gross Margin | 46.8% | 72.5% |
| Operating Margin | 19.4% | 20.2% |
| Net Margin | 13.3% | 12.2% |
| Revenue YoY | -1.8% | -1.6% |
| Net Profit YoY | -35.7% | 36.8% |
| EPS (diluted) | $0.51 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $187.0M | ||
| Q3 25 | $191.8M | $188.7M | ||
| Q2 25 | $174.4M | $188.8M | ||
| Q1 25 | $170.5M | $188.4M | ||
| Q4 24 | $186.5M | $190.1M | ||
| Q3 24 | $191.2M | $193.6M | ||
| Q2 24 | $182.4M | $190.4M | ||
| Q1 24 | $171.8M | $196.1M |
| Q4 25 | $24.4M | $22.9M | ||
| Q3 25 | $17.4M | $18.4M | ||
| Q2 25 | $31.0M | $19.5M | ||
| Q1 25 | $25.3M | $13.0M | ||
| Q4 24 | $38.0M | $16.7M | ||
| Q3 24 | $40.4M | $18.7M | ||
| Q2 24 | $37.9M | $17.1M | ||
| Q1 24 | $43.2M | $59.0M |
| Q4 25 | 46.8% | 72.5% | ||
| Q3 25 | 51.4% | 70.7% | ||
| Q2 25 | 49.6% | 70.5% | ||
| Q1 25 | 50.0% | 70.7% | ||
| Q4 24 | 46.5% | 72.5% | ||
| Q3 24 | 53.3% | 72.8% | ||
| Q2 24 | 52.2% | 72.6% | ||
| Q1 24 | 52.4% | 72.1% |
| Q4 25 | 19.4% | 20.2% | ||
| Q3 25 | 13.2% | 15.8% | ||
| Q2 25 | 24.2% | 16.5% | ||
| Q1 25 | 21.9% | 11.0% | ||
| Q4 24 | 24.2% | 14.5% | ||
| Q3 24 | 29.8% | 15.8% | ||
| Q2 24 | 30.3% | 17.2% | ||
| Q1 24 | 27.9% | 48.9% |
| Q4 25 | 13.3% | 12.2% | ||
| Q3 25 | 9.0% | 9.8% | ||
| Q2 25 | 17.8% | 10.3% | ||
| Q1 25 | 14.8% | 6.9% | ||
| Q4 24 | 20.4% | 8.8% | ||
| Q3 24 | 21.1% | 9.7% | ||
| Q2 24 | 20.8% | 9.0% | ||
| Q1 24 | 25.1% | 30.1% |
| Q4 25 | $0.51 | $0.23 | ||
| Q3 25 | $0.37 | $0.17 | ||
| Q2 25 | $0.64 | $0.19 | ||
| Q1 25 | $0.51 | $0.10 | ||
| Q4 24 | $0.74 | $0.19 | ||
| Q3 24 | $0.78 | $0.18 | ||
| Q2 24 | $0.73 | $0.16 | ||
| Q1 24 | $0.81 | $0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $23.3M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $946.0M |
| Total Assets | $1.6B | $5.1B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $23.3M | ||
| Q3 25 | $276.2M | $26.3M | ||
| Q2 25 | $231.8M | $26.1M | ||
| Q1 25 | $236.9M | $19.3M | ||
| Q4 24 | $221.6M | $50.4M | ||
| Q3 24 | $250.5M | $69.9M | ||
| Q2 24 | $217.8M | $59.0M | ||
| Q1 24 | $289.6M | $64.2M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $946.0M | ||
| Q3 25 | $776.7M | $973.1M | ||
| Q2 25 | $757.5M | $1.0B | ||
| Q1 25 | $751.3M | $1.0B | ||
| Q4 24 | $732.3M | $1.1B | ||
| Q3 24 | $727.7M | $986.9M | ||
| Q2 24 | $713.3M | $1.2B | ||
| Q1 24 | $672.4M | $1.3B |
| Q4 25 | $1.6B | $5.1B | ||
| Q3 25 | $1.7B | $5.1B | ||
| Q2 25 | $1.6B | $5.2B | ||
| Q1 25 | $1.6B | $5.3B | ||
| Q4 24 | $1.6B | $5.4B | ||
| Q3 24 | $1.5B | $5.4B | ||
| Q2 24 | $1.5B | $5.3B | ||
| Q1 24 | $1.6B | $5.4B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $338.5M |
| Free Cash FlowOCF − Capex | $24.6M | $299.8M |
| FCF MarginFCF / Revenue | 13.4% | 160.3% |
| Capex IntensityCapex / Revenue | 4.5% | 20.7% |
| Cash ConversionOCF / Net Profit | 1.35× | 14.79× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $541.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $338.5M | ||
| Q3 25 | $52.6M | $100.2M | ||
| Q2 25 | $35.6M | $79.9M | ||
| Q1 25 | $35.1M | $85.6M | ||
| Q4 24 | $29.0M | $363.1M | ||
| Q3 24 | $60.0M | $105.7M | ||
| Q2 24 | $69.1M | $83.2M | ||
| Q1 24 | $55.3M | $94.0M |
| Q4 25 | $24.6M | $299.8M | ||
| Q3 25 | $47.2M | $88.0M | ||
| Q2 25 | $25.0M | $73.8M | ||
| Q1 25 | $24.4M | $79.9M | ||
| Q4 24 | $16.6M | $344.4M | ||
| Q3 24 | $46.2M | $101.8M | ||
| Q2 24 | $63.1M | $79.5M | ||
| Q1 24 | $46.5M | $88.6M |
| Q4 25 | 13.4% | 160.3% | ||
| Q3 25 | 24.6% | 46.6% | ||
| Q2 25 | 14.3% | 39.1% | ||
| Q1 25 | 14.3% | 42.4% | ||
| Q4 24 | 8.9% | 181.2% | ||
| Q3 24 | 24.1% | 52.6% | ||
| Q2 24 | 34.6% | 41.7% | ||
| Q1 24 | 27.1% | 45.2% |
| Q4 25 | 4.5% | 20.7% | ||
| Q3 25 | 2.8% | 6.5% | ||
| Q2 25 | 6.1% | 3.2% | ||
| Q1 25 | 6.3% | 3.0% | ||
| Q4 24 | 6.7% | 9.8% | ||
| Q3 24 | 7.2% | 2.0% | ||
| Q2 24 | 3.3% | 1.9% | ||
| Q1 24 | 5.1% | 2.7% |
| Q4 25 | 1.35× | 14.79× | ||
| Q3 25 | 3.03× | 5.44× | ||
| Q2 25 | 1.15× | 4.10× | ||
| Q1 25 | 1.39× | 6.59× | ||
| Q4 24 | 0.76× | 21.70× | ||
| Q3 24 | 1.48× | 5.65× | ||
| Q2 24 | 1.82× | 4.88× | ||
| Q1 24 | 1.28× | 1.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
NSA
Segment breakdown not available.
